SB 204741
目录号 : GC12803
SB 204741是一种选择性且高亲和力的5-HT2B受体拮抗剂，其pKi值为7.1。
Cas No.:152239-46-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
SB 204741 is a selective and high affinity 5-HT2B antagonist with a pKi value of 7.1[1]. 5-HT2B receptor is a serotonin receptor subtype closely associated with cardiovascular remodeling, fibrosis, and inflammatory responses[2]. SB 204741 is commonly used in the research of cardiovascular diseases[3].
In vitro, SB 204741 (30µM; 30min) completely blocked the potentiating effect of a-Me-5-HT on N-methyl-D-aspartate(NMDA)-induced depolarizations, and inhibited the G-protein-coupled 5-HT2B-NMDA cross-signaling in frog motoneurones[4]. Treatment of TGF-β1-stimulated human peritoneal fibroblasts (HPFBs) with SB 204741 (1µM; 24h) significantly reduced the expression of profibrotic genes(COL1A1, COL1A2, ACTA2, CTGF, FN1, and TGF-B1) and pro-inflammatory cytokines(IFN-γ, IL-4, IL-17, IL-1β, IL-6, TNF-α), and increased anti-inflammatory cytokine IL-10 levels[5].
In vivo, SB 204741 (0.5mg/kg; i.p.; single administration) significantly decreased the percentage maximal possible effect (%MPE) in both tail-flick (TF) and hot-plate (HP) assays in rats exposed to 5mT electromagnetic field (EMF), and reduced analgesic activity in the EMF-induced analgesia model[6]. SB 204741 (1mg/kg/day; i.p.; 28 days) significantly reduced heart weight/body weight ratio, left ventricular weight/body weight ratio, myocyte area and interstitial fibrosis, improved mean arterial pressure, left ventricular end diastolic pressure, rate of contraction and rate of relaxation, and decreased hypertrophic, inflammatory and apoptotic markers while increasing Bcl-2 expression and phosphorylation of Akt/GSK-3β/β-catenin/eNOS in isoproterenol-induced cardiac hypertrophy in rats[7].
References:
[1] Bonhaus DW, Bach C, DeSouza A, et al. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol. 1995;115(4):622-628.
[2] McCorvy JD, Roth BL. Structure and function of serotonin G protein-coupled receptors. Pharmacol Ther. 2015;150:129-142.
[3] Bai CF, Liu JC, Zhao R, et al. Role of 5-HT 2B receptors in cardiomyocyte apoptosis in noradrenaline-induced cardiomyopathy in rats. Clin Exp Pharmacol Physiol. 2010;37(7):e145-e151.
[4] Holohean AM, Hackman JC. Mechanisms intrinsic to 5-HT2B receptor-induced potentiation of NMDA receptor responses in frog motoneurones. Br J Pharmacol. 2004;143(3):351-360.
[5] Chaturvedi S, Singh H, Agarwal V, Jaiswal A, Prasad N. Unravelling the role of Sildenafil and SB204741 in suppressing fibrotic potential of peritoneal fibroblasts obtained from PD patients. Front Pharmacol. 2024;14:1279330.
[6] Ozdemir E, Demirkazik A, Taskıran AS, Arslan G. Effects of 5-HT1 and 5-HT 2 Receptor Agonists on Electromagnetic Field-Induced Analgesia in Rats. Bioelectromagnetics. 2019;40(5):319-330.
[7] Bharti S, Singh R, Chauhan SS, Hussain T, Al-Attas OS, Arya DS. Phosphorylation of Akt/GSK-3β/eNOS amplifies 5-HT2B receptor blockade mediated anti-hypertrophic effect in rats. FEBS Lett. 2012;586(2):180-185.
SB 204741是一种选择性且高亲和力的5-HT2B受体拮抗剂，其pKi值为7.1[1]。5-HT2B受体是一种与心血管重塑、纤维化及炎症反应密切相关的血清素受体亚型[2]。SB 204741常用于心血管疾病的研究[3]。
在体外实验中，SB 204741（30µM；30分钟）完全阻断了a-Me-5-HT对N-甲基-D-天门冬氨酸（NMDA）诱导的蛙运动神经元去极化的增强作用，并抑制了蛙运动神经元中G蛋白偶联的5-HT2B-NMDA交叉信号[4]。在TGF-β1刺激的人腹膜成纤维细胞（HPFBs）中，SB 204741（1µM；24小时）显著降低了促纤维化基因（COL1A1、COL1A2、ACTA2、CTGF、FN1 和 TGF-B1）和促炎细胞因子（IFN-γ、IL-4、IL-17、IL-1β、IL-6、TNF-α）的表达，并增加了抗炎细胞因子IL-10的水平[5]。
在体内实验中，SB 204741（0.5mg/kg；腹腔注射；单次给药）显著降低了在5mT电磁场（EMF）暴露的大鼠在甩尾（TF）和热板（HP）试验中的最大可能效应百分比（%MPE），减少了EMF诱导的镇痛模型中的镇痛活性[6]。SB 204741（1mg/kg/天；腹腔注射；28天）显著降低了异丙肾上腺素诱导的心脏肥大大鼠的心重/体重比、左心室重/体重比、心肌细胞面积和间质纤维化，改善了平均动脉压、左心室舒张末期压、收缩率和舒张率，并降低了肥大、炎症和凋亡标志物，同时增加了Bcl-2表达和Akt/GSK-3β/β-catenin/eNOS的磷酸化[7]。
| Cell experiment [1]: | |
Cell lines | human peritoneal fibroblasts (HPFBs) |
Preparation Method | A total of 1×106 cells/well were seeded in 6-well plates for 24h. Following adherence, HPFBs were synchronized by incubating them with 2% DMEM for 24h. HPFBs were initially treated with TGF-β1 (10ng/mL) for 1h and later incubated with TGF-β1 (10ng/mL) and SB 204741 ( 1µM) for 24h. HPFBs obtained from the above two strategies were used for RNA extraction, and further quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed. |
Reaction Conditions | 1μM; 24h |
Applications | SB 204741 significantly reduced the expression of profibrotic genes and pro-inflammatory cytokines, and increased anti-inflammatory cytokine IL-10 levels in TGF-β1-stimulated HPFBs after 24 hours of treatment. |
| Animal experiment [2]: | |
Animal models | Male wistar rats |
Preparation Method | Male wistar rats (150–170g) were divided into 3 groups (n = 8) and were administered vehicle or drugs for 28 days. Group 1 (NC): vehicle (0.3ml H2O, i.p.). Group 2 (ISO): isoproterenol (3mg/kg/day, s.c.). Group 3 (ISO+SB): isoproterenol (3mg/kg/day, s.c.) plus SB 204741 (1mg/kg/day, i.p.). After recording the hemodynamic parameters, animals of all the groups were sacrificed with an overdose of anesthesia (sodium pentobarbitone 100mg/kg, i.v.) and their hearts were excised and processed for various parameters. In addition, blood was withdrawn via cardiac puncture and centrifuged at 3000g for 5 min for measuring serum CK-MB, CRP and BNP levels. |
Dosage form | 1mg/kg/day; i.p.; 28 days |
Applications | SB 204741 significantly reduced heart weight/body weight ratio, left ventricular weight/body weight ratio, myocyte area and interstitial fibrosis in isoproterenol-induced cardiac hypertrophy in rats. |
References: | |
| Cas No. | 152239-46-8 | SDF | |
| 化学名 | 1-(1-methyl-1H-indol-5-yl)-3-(3-methylisothiazol-5-yl)urea | ||
| Canonical SMILES | O=C(NC1=CC(C)=NS1)NC2=CC=C3N(C)C=CC3=C2 | ||
| 分子式 | C14H14N4OS | 分子量 | 286.35 |
| 溶解度 | <5.73mg/ml in ethanol; <28.64mg/ml in DMSO | 储存条件 | Store at 2-8℃ |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4922 mL | 17.4611 mL | 34.9223 mL |
| 5 mM | 0.6984 mL | 3.4922 mL | 6.9845 mL |
| 10 mM | 0.3492 mL | 1.7461 mL | 3.4922 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet